Literature DB >> 20073610

Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker.

Jane Y Dancer1, Luan D Truong, Qihui Zhai, Steven S Shen.   

Abstract

CONTEXT: Galectin-3, a member of the lectin family, was shown to be expressed in normal distal tubular cells and in renal cell carcinomas (RCC). However, its diagnostic and prognostic significance in RCC is as yet undefined.
OBJECTIVES: To describe the expression of Galectin-3 among different histologic subtypes of renal neoplasms and to determine their diagnostic and prognostic significances.
DESIGN: The expression of Galectin-3 was evaluated in 217 renal neoplasms by tissue microarray and immunohistochemistry with semiquantitative analysis.
RESULTS: Strong expression of Galectin-3 was observed in 92 of 217 of renal neoplasms (42.4%). Although 22 of 23 oncocytomas (95.7%) and 19 of 21 chromophobe RCCs (90.5%) express Galectin-3, only 4 of 32 papillary RCCs (12.5%) and 47 of 137 clear cell RCCs (34.3%) express Galectin-3, suggesting that it may be used as a potential diagnostic marker. Galectin-3 expression was seen in 55% of high-grade (Fuhrman nuclear grades 3 and 4) versus 21% low-grade (grades 1 and 2) clear cell RCCs (P < .001).
CONCLUSIONS: This study confirms that Galactin-3 is strongly overexpressed in renal cell neoplasms of distal tubular differentiation, that is, oncocytoma and chromophobe RCCs, suggesting it might be used as a possible differential diagnostic tool for renal cell neoplasm with oncocytic or granular cells. Furthermore, we observed a strong association of overexpression of Galectin-3 and high nuclear grade in clear cell RCC. These results also suggest a possible pivotal role for Galectin-3 in the differentiation and prognosis of clear cell RCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20073610     DOI: 10.5858/2008-0392-OAR1.1

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  Antitumor effects of galectin-3 inhibition in human renal carcinoma cells.

Authors:  Yangyang Xu; Changfu Li; Jiahang Sun; Jingshu Li; Xin Gu; Wanhai Xu
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-03

2.  Comprehensive analysis of cellular galectin-3 reveals no consistent oncogenic function in pancreatic cancer cells.

Authors:  Alexander Hann; Anja Gruner; Ying Chen; Thomas M Gress; Malte Buchholz
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

3.  Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma.

Authors:  Tamara Straube; Alexandra F Elli; Christoph Greb; Axel Hegele; Hans-Peter Elsässer; Delphine Delacour; Ralf Jacob
Journal:  J Exp Clin Cancer Res       Date:  2011-09-29

4.  Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.

Authors:  Deepa M Gopal; Maya Kommineni; Nir Ayalon; Christian Koelbl; Rivka Ayalon; Andreia Biolo; Laura M Dember; Jill Downing; Deborah A Siwik; Chang-Seng Liang; Wilson S Colucci
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

5.  High expression of galectin-7 associates with poor overall survival in patients with non-metastatic clear-cell renal cell carcinoma.

Authors:  Jieti Wang; Yidong Liu; Yuanfeng Yang; Zhiying Xu; Guodong Zhang; Zheng Liu; Hangcheng Fu; Zewei Wang; Haiou Liu; Jiejie Xu
Journal:  Oncotarget       Date:  2016-07-05

Review 6.  Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.

Authors:  Salvatore Sciacchitano; Luca Lavra; Alessandra Morgante; Alessandra Ulivieri; Fiorenza Magi; Gian Paolo De Francesco; Carlo Bellotti; Leila B Salehi; Alberto Ricci
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.